FibroGen (1FG0) Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1FG0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.40 |
| 52 Week High | US$17.50 |
| 52 Week Low | US$5.30 |
| Beta | 0.77 |
| 1 Month Change | 9.63% |
| 3 Month Change | -19.13% |
| 1 Year Change | -52.15% |
| 3 Year Change | -98.39% |
| 5 Year Change | -99.06% |
| Change since IPO | -98.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FG0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | 4.0% | 1.5% |
| 1Y | -52.2% | -34.7% | 14.1% |
Return vs Industry: 1FG0 underperformed the German Biotechs industry which returned -30.1% over the past year.
Return vs Market: 1FG0 underperformed the German Market which returned 14.5% over the past year.
Price Volatility
| 1FG0 volatility | |
|---|---|
| 1FG0 Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1FG0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1FG0's weekly volatility has decreased from 21% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 225 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors.
FibroGen, Inc. Fundamentals Summary
| 1FG0 fundamental statistics | |
|---|---|
| Market cap | €30.90m |
| Earnings (TTM) | -€44.70m |
| Revenue (TTM) | €7.10m |
Is 1FG0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FG0 income statement (TTM) | |
|---|---|
| Revenue | US$8.30m |
| Cost of Revenue | US$38.65m |
| Gross Profit | -US$30.35m |
| Other Expenses | US$21.91m |
| Earnings | -US$52.26m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.92 |
| Gross Margin | -365.76% |
| Net Profit Margin | -629.78% |
| Debt/Equity Ratio | 111.4% |
How did 1FG0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 21:25 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FibroGen, Inc. is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Matthew Keller | H.C. Wainwright & Co. |
| Xiaodong Zhang | H.C. Wainwright & Co. |